Pharmaceutical raw materials with greater control for demanding processes
In the pharmaceutical industry, every raw material matters. A correct specification is important, but it is not always enough. When a project operates under strict quality, audit, or regulatory requirements, the real value comes from well-documented materials, appropriate controls, and a supplier able to provide technical support from the early stages of assessment.
PharmaFine® is the line of pharmaceutical raw materials and excipients from DC Fine Chemicals, designed for customers working in high-control environments. Its purpose is to support raw material assessment and qualification through technical information, traceability, documentation, and additional controls depending on the product.
This line may be considered by customers for processes where a more demanding material assessment is required, including projects related to parenteral applications, always subject to the customer’s own final evaluation, validation, and approval.
Raw materials for assessment in parenteral applications
Parenteral applications require especially careful assessment of the raw materials used in the process. In these cases, QA, development, production, and regulatory affairs teams often need additional information on endotoxins, microbiological content, elemental impurities, residual solvents, traceability, and handling conditions.
PharmaFine® does not define or guarantee the final suitability of a raw material for a specific parenteral application. What it provides is a more complete analytical and documentary basis so that each customer can perform its own risk assessment, internal qualification, and final use approval.
This approach allows customers to work with more information from the beginning, reduce uncertainty, and facilitate the technical, documentary, and regulatory review of the material.
Endotoxin and microbiological control
For quality teams, confidence depends on clear data: which controls have been performed, what documentation is available, which risks have been considered, and what information can be presented during an audit or internal review.
PharmaFine® helps answer these questions with a more structured approach. Depending on the category and product, it may include microbiological analysis, endotoxin control, technical documentation, and support for material assessment.
For PharmaFine® products defined under this approach, each batch may be assessed and released according to established limits for:
- BET / Bacterial Endotoxins Test
- MLT / Microbial Limits Test
- Batch-related documentary review
This additional control helps QA and regulatory affairs teams work with a clearer basis, reducing doubts and avoiding unnecessary delays during qualification.
Assessment aligned with demanding pharmaceutical processes
In addition to microbiological and endotoxin control, selected PharmaFine® products may include information or documentary assessment related to international guidelines relevant to the pharmaceutical industry, such as:
- ICH Q3C, for the assessment of residual solvents
- ICH Q3D, for the assessment of elemental impurities
The availability of this information depends on the product, grade, process, and documentary scope required by the customer.
PharmaFine® is also supported by quality standards and resources relevant to pharmaceutical environments, including EXCiPACT certification, the availability of a third-party GMP audit, and production or handling in a Cleanroom ISO Class 8, equivalent to EU GMP Grade D, when applicable.
Together, these elements support a more organized, traceable, and controlled way of working with pharmaceutical raw materials in demanding processes.
Support for audits, qualification, and documentation
In demanding pharmaceutical projects, a raw material is not assessed only by its specification. It is also assessed by the documentation available, the supplier’s responsiveness, and the consistency of the controls applied.
PharmaFine® is designed to support this process through:
- Product technical documentation
- Batch certificates of analysis
- Endotoxin and microbiological information when applicable
- Assessment related to ICH Q3C and ICH Q3D when relevant
- Documentary support for qualification processes
- Possibility of audit or additional review depending on the project scope
This approach helps reduce open questions during audits, internal reviews, or raw material approval processes.
Less uncertainty for QA and regulatory affairs teams
For quality, development, and regulatory affairs teams, working with a well-documented raw material can make an important difference.
Greater data availability helps teams to:
- Assess risk more clearly
- Reduce delays during qualification
- Better prepare internal documentation
- Respond more confidently during audits
- Align the raw material with process requirements from an early stage
In this sense, PharmaFine® does not replace the customer’s own evaluation, but it does provide a stronger basis to support it.
PharmaFine® products available for assessment
DC Fine Chemicals offers a selection of PharmaFine® raw materials that may be assessed by customers for high-control pharmaceutical processes.
The availability of tests, microbiological limits, BET, ICH Q3C documentation, ICH Q3D documentation, or handling in Cleanroom ISO Class 8 / EU GMP Grade D may vary depending on the product. Our technical team can review each case and confirm the available documentation to support the customer’s internal assessment.
Consult our PharmaFine® product list or contact our team to review the technical and documentary requirements of your project.
Important note on final use
The information provided by DC Fine Chemicals is intended to support the technical, documentary, and regulatory assessment of each raw material. The suitability, qualification, validation, and approval of the product for a specific final application, including parenteral applications, must be determined exclusively by the customer.